ACTR 707

Drug Profile

ACTR 707

Alternative Names: ACTR707

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unum Therapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I B cell lymphoma
  • Preclinical Solid tumours

Most Recent Events

  • 13 Aug 2018 The US FDA approves IND application for ACTR 707 in combination with trastuzumab in Solid tumours
  • 13 Aug 2018 Unum Therapeutics plans the phase I ATTCK-34-01 trial for HER2+ Solid tumours in combination with trastuzumab (Late stage disease) in the second half of 2018
  • 14 May 2018 Unum Therapeutics announces intention to submit IND to the US FDA for Solid tumours (Combination therapy with trastuzumab) in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top